Vaccination centers in Europe are standing ready — but no vaccine is available. Pfizer has cut its production, and AstraZeneca has announced it would be delivering 60% less than agreed with the EU.
Worldwide, the number of potential pathogens is very large, while the resources for disease research and development (R&D) is limited. To ensure efforts under WHO’s R&D Blueprint are focused and productive, a list of diseases and pathogens are prioritized for R&D in public health emergency contexts.
